Convenience, accuracy and efficiency all in one

Single-use 100-mL bags available in the following dosage forms and strengths:

Levetiracetam in 0.82% sodium chloride injection (500 mg/100 mL)
Levetiracetam in 0.75% sodium chloride injection (1000 mg/100 mL)
Levetiracetam in 0.54% sodium chloride injection (1500 mg/100 mL)

Simple preparation and administration

Premixed and ready to administer, no dilution required
Levetiracetam in Sodium Chloride Injection is administered as a 15-minute IV infusion.

Clear identification

Prelabeled, color-coded doses available in 3 strengths

Easy access

Single-use, 100-mL dual port bag

Click here for full Prescribing Information.

Dosing instructions

Starting dose: 1000 mg/day, given as 500 mg twice daily
Dose increase: Every 2 weeks by 1000 mg/day as needed and tolerated to the recommended dose of 3000 mg/day.^✽
For adult patients with impaired renal function, dosing must be individualized according to patient's renal function status. Please see full Prescribing Information for additional information.
Patients should be advised to notify their physician if they are pregnant prior to therapy.

Storage instructions

Store at 20°C to 25°C (68°F to 77°F)
Physically compatible and chemically stable for at least 24 hours when mixed with lorazepam, diazepam, and valproate sodium and stored at controlled room temperature 15°C to 30°C (59°F to 86°F)
Shelf life is 18 months.

New Levetiracetam in Sodium Chloride Injection

Click to See Full Size Chart

NDC Number	Strength	Wholesaler Number

67457-255-10	500 mg (100 mL)	AmerisourceBergen 152715 Cardinal 4552394 McKesson 2453124 Morris and Dickson 246082
67457-265-10	1000 mg (100 mL)	AmerisourceBergen 152710 Cardinal 4552337 McKesson 2453249 Morris and Dickson 246090
67457-266-10	1500 mg (100 mL)	AmerisourceBergen 152708 Cardinal 4552253 McKesson 2453710 Morris and Dickson 246322

Please note: All strengths available in packages of 10.

For more information, please call Customer Service at 1.888.258.4199.

Important Safety Information

Levetiracetam in Sodium Chloride Injection is an antiepileptic drug indicated when oral administration is temporarily not feasible in adults (16 years and older) with: partial onset seizures; myoclonic seizures in patients with juvenile myoclonic epilepsy; primary generalized tonic-clonic seizures.

Levetiracetam should be gradually withdrawn to minimize the potential of increased seizure frequency.

Antiepileptic drugs (AEDs) increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Levetiracetam in Sodium Chloride Injection causes neuropsychiatric reactions including somnolence and fatigue, muscle coordination difficulties and behavioral abnormalities as well as hematological abnormalities. The most common adverse reactions observed with Levetiracetam were somnolence, weakness, infection and dizziness. Important behavioral adverse reactions include hallucinations, delusions, and non-psychotic mood disorders including suicide ideation, aggression, anger, apathy, conduct disorder, irritability, depression, nervousness, anxiety and emotional lability.

Dosing must be individualized according to seizure type, patient's renal function status and therapy objective. Based on animal data, Levetiracetam may cause fetal harm and therefore should be used during pregnancy after consideration of the potential benefit-risk ratio. Levetiracetam should be gradually withdrawn to minimize the potential of increased seizure frequency.

Click here for full Prescribing Information.

^✽ Please refer to the full Prescribing Information regarding the following:

3000 mg/day is the maximum recommended dose for partial onset seizures.
The effectiveness of doses lower than 3000 mg/day has not been studied in treating myoclonic seizures in patients with juvenile myoclonic epilepsy.
The effectiveness of doses lower than 3000 mg/day has not been adequately studied in patients with primary generalized tonic-clonic seizures.